EARLY DIALOGUE WITH NICE AND EUNETHTA- A UK PERSPECTIVE IN A POLITICALLY UNCERTAIN ERA

Author(s)

Heyes A1, Millar L2
1RTI Health Solutions, Manchester, UK, 2National Institute for Health and Care Excellence, Didsbury, LAN, UK

OBJECTIVES

The National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK) and the European Network for Health Technology Assessment (EUnetHTA), a network of HTA bodies, including the UK, offer manufacturers the opportunity to engage in early dialogue (ED) regarding specific evidence requirements for products in development. Recommendations inform evidence generation within and outside the clinical programme for future HTA product submissions. This review compares HTA ED processes offered by EUnetHTA and NICE, provides information on good quality interactions for manufacturers, and describes new service options introduced by NICE, including contingency plans should the UK leave the European Union (EU).

METHODS

A targeted review of literature and Internet-based sources identified the most recent information on ED processes provided by NICE and EUnetHTA. Both offer joint regulatory and HTA advice; this review focused on the HTA advice process.

RESULTS

The EUnetHTA ED process involves the ED Working Party (EDWP) with agencies from France, Germany, Hungary, Italy, UK, Belgium, and The Netherlands; additional HTA bodies may participate in EDs as required. Manufacturers submit a briefing book with product and disease information, plus specific questions on clinical and economic issues for HTA. NICE employs a similar overall process and in April 2019 introduced different options, including an express service and choice of more limited expert review. EUnetHTA and NICE include the opportunity for face-to-face discussion plus written recommendations. NICE has published steps to ensure continuity of service if the UK leaves the EU.

CONCLUSIONS

EUnetHTA and NICE ED services have similar process structures but differ in breadth of country feedback and flexibility of scope. The optimal time for seeking ED is preinitiation of main registration efficacy studies, aiding appropriate study design for HTA and regulatory review; alternatively, ED sought during study conduct informs the approach to economic analysis.

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark

Code

PNS262

Topic

Health Policy & Regulatory, Health Technology Assessment, Organizational Practices

Topic Subcategory

Best Research Practices, Reimbursement & Access Policy, Systems & Structure

Disease

No Specific Disease

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×